Now you can fly to the Netherlands for Ampligen!
PHILADELPHIA, July 25,
2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced
today that the first order of rintatolimod (Ampligen®) for the Early
Access Program (EAP) in Europe has been shipped with receipt confirmed
on July 22. On May 23, 2016, the Company executed an amended and
restated agreement with Impatients N.V., a Netherlands-based company
operating as myTomorrows, for the commencement and management of an
Early Access Program (EAP) in all of Europe and Turkey. Ampligen® is the
trade name in the United States for rintatolimod.
“This
program will enable Chronic Fatigue Syndrome (CFS) patients, who face an
unmet medical need in the EU, to access rintatolimod under early access
regulations,” said Tom Equels, CEO of Hemispherx. “It will operate
concurrently while we work with the FDA to determine a path toward
approval in the United States. The initiation and implementation of our
EAP out-reach is an important tangible step in our effort to make our
experimental drug Ampligen® a commercially approved drug available to
all those suffering from CFS.”http://globenewswire.com/news-release/2016/07/25/858585/0/en/Hemispherx-Announces-First-Shipment-of-Rintatolimod-Ampligen-to-Early-Access-Program-in-Europe.html?f=22&fvtc=9&fvtv=us